Prepaid multi-month plans lower the monthly rate but can be hard to refund if you stop early.
Prepaid plans require paying the full term up front. If side effects or a regulatory change interrupt treatment, refunds may be limited. Read the cancellation and refund terms before prepaying, and confirm what happens if the medication becomes unavailable.
| What to know |
|---|
| Prepaid multi-month plans lower the monthly rate but can be hard to refund if you stop early. |
| Prepaid plans require paying the full term up front. |
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list; public comments are due by Jun 29, 2026. Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.